COMUNICADO: European Commission Grants Marketing Authorisation to Humalog® 200 units/ml KwikPen(TM) Insulin

— First 200 units/ml rapid-acting insulin product for the treatment of diabetes

INDIANAPOLIS, Oct. 3, 2014 /PRNewswire/ — Eli Lilly and Company today announced that the European Commission has granted marketing authorisation for Humalog® 200 units/ml KwikPen(TM) (insulin lispro 200 units/ml) for the treatment of diabetes in adults.

Enlace a la fuente orginal del artículo: http://www.europapress.es/comunicados/internacional/noticia-comunicado-european-commission-grants-marketing-authorisation-to-humalog-200-units-ml-kwikpentm-insulin-20141003100040.html

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *